Durvalumab plus tremelimumab for the treatment of patients (pts) with refractory and progressive advanced thyroid carcinoma: A phase II multicohort trial (DUTHY / GETNE T1812)

被引：0
|
作者：
Hernando Cubero, J. [1 ]
Taberna Sanz, M. [2 ]
Carmona Bayonas, A. [3 ]
Iglesias, L. [4 ]
Grande, E. [5 ]
Trigo Perez, J. M. [6 ]
Grau, J. J. [7 ]
Lopez-Picazo, J. M. [8 ]
Castelo, B. [9 ]
Alonso Gordoa, T. [10 ]
Lorenzo, I. [11 ]
Casado Herraez, A. [12 ]
Ugidos, L. [13 ]
Munarriz, J. [14 ]
Lavernia, J. [15 ]
Capdevila, J. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
[2] Hosp Duran & Reynals, ICO, Med Oncol, Lhospitalet De Llobregat, Spain
[3] Hosp Univ Morales Meseguer, Hematol & Med Oncol, Murcia, Spain
[4] Univ Hosp 12 Octubre, Oncol, Madrid, Spain
[5] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain
[6] Hosp Univ Virgen de la Victoria, Med Oncol, Malaga, Spain
[7] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
[8] Clin Univ Navarra, Med Oncol, Pamplona, Spain
[9] Hosp Univ La Paz, Med Oncol, Madrid, Spain
[10] Hosp Univ Ramon y Cajal, Med Oncol, Madrid, Spain
[11] Complejo Hosp Univ Vigo, Med Oncol, Vigo, Spain
[12] Hosp Clin Univ San Carlos, Dept Med Oncol, Madrid, Spain
[13] HM San Chinarro, Med Oncol, Madrid, Spain
[14] Hosp Gen Castellon, Med Oncol, Castellon de La Plana, Spain
[15] Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1872TiP
引用
收藏
页码：759 / 759
页数：1
相关论文
共 50 条
  • [1] Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial
    Castillon, J. Capdevila
    Plana, M.
    Castelo, B.
    Iglesias, L.
    Hernando, J.
    Tur, R. Yaya
    Baste, N.
    Carmona-Bayonas, A.
    Ruiz, S.
    Trigo, J.
    Lorenzo-Lorenzo, I.
    Grande, E.
    Lorente, D.
    Ugidos, L.
    Marquina, G.
    Garcia-Alvarez, A.
    Taberna, M.
    Villamayor, J.
    Molina-Cerrillo, J.
    Alonso-Gordoa, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1294 - S1295
  • [2] Durvalumab (D) plus Tremelimumab (T) for the treatment of patients with progressive, advanced medullary thyroid carcinoma (MTC) - DUTHY (GETNE-T1812) trial
    Garcia-Alvarez, A.
    Molina-Cerrillo, J.
    Castelo, B.
    Plana, M.
    Iglesias, L.
    Carmona-Bayonas, A.
    Yaya, Tur R.
    Ruiz, S.
    Baste, N.
    Lorenzo-Lorenzo, I
    Alonso-Gordoa, T.
    Capdevila, J.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 236 - 236
  • [3] Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) of Lung or Gastroenteropancreatic (GEP) Origin. A Phase II Multicohort Trial (DUNE Trial / GETNE 1601)
    Hernando-Cubero, J.
    Manzano, J. L.
    Benavent, M.
    Lopez, C.
    Teule, R.
    Garcia-Carbonero, R.
    Carmona-Bayonas, A.
    Crespo, G.
    Cubillo, A.
    Jimenez-Fonseca, P.
    LaCasta, A.
    Capdevila, J.
    NEUROENDOCRINOLOGY, 2018, 106 : 228 - 228
  • [4] A multicohort phase II study of durvalumab plus tremelimumab for the treatment of patients (PTS) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or lung origin (the DUNE trial-GETNE1601-).
    Garcia, Ignacio Matos
    Grande, Enrique
    Garcia-Carbonero, Rocio
    Lopez, Carlos
    Teule, Alexandre
    Capdevila, Jaume
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
    Capdevila, J.
    Teule, A.
    Lopez, C.
    Garcia-Carbonero, R.
    Benavent, M.
    Custodio, A.
    Cubillo, A.
    Alonso, V.
    Alonso Gordoa, T.
    Carmona-Bayonas, A.
    Crespo, G.
    Blanco-Codesido, M.
    Jimenez-Fonseca, P.
    Viudez, A.
    La Casta Munoa, A.
    Sevilla, I.
    Llanos, M.
    Segura, A.
    Hernando-Cubero, J.
    Manzano, J. L.
    ANNALS OF ONCOLOGY, 2020, 31 : S770 - S771
  • [6] Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914)
    Grande, E.
    Garcia-Carbonero, R.
    Teule, A.
    Benavent Vinuales, M.
    Jimenez-Fonseca, P.
    Molina-Cerrillo, J.
    Lopez, C.
    Custodio, A.
    Hierro, C.
    Gallego, J.
    Alonso, V.
    Carmona-Bayonas, A.
    Llanos, M.
    Sevilla, I.
    Hernando, J.
    Lista, F.
    Anton Pascual, B.
    Ruffinelli, J. C.
    Gallego Jimenez, I.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S624 - S625
  • [7] CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
    Chen, Eric Xueyu
    Jonker, Derek J.
    Kennecke, Hagen F.
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl L.
    Wei, Alice Chia-chi
    Magoski, Nadine M.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [8] Sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory thyroid carcinoma and anaplastic thyroid carcinoma: The phase II SETHY, GETNE-T2318 trial design
    Garcia Alvarez, A.
    Castelo Fernandez, B.
    Lopez, C.
    Martinez-Trufero, J.
    Alonso-Gordoa, T.
    Carmona-Bayonas, A.
    Marquin, G.
    Martinez-Lago, N.
    Jimenez-Fonseca, P.
    Plana Serrahima, M.
    Grande, E.
    Hernando, J.
    Capdevila Castillon, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1125 - S1126
  • [9] Phase Ib trial of durvalumab plus tremelimumab in combination with particle radiotherapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial
    Ogasawara, Sadahisa
    Koroki, Keisuke
    Makishima, Hirokazu
    Wakatsuki, Masaru
    Sakuma, Takafumi
    Fujita, Naoto
    Kanzaki, Hiroaki
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Kanogawa, Naoya
    Saito, Tomoko
    Kondo, Takayuki
    Nakagawa, Ryo
    Nakamoto, Shingo
    Muroyama, Ryosuke
    Chiba, Tetsuhiro
    Hanaoka, Hideki
    Tsuji, Hiroshi
    Kato, Naoya
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [10] Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601)
    Capdevila, J.
    Landolfi, S.
    Hernando, J.
    Teule, A.
    Garcia-Carbonero, R.
    Custodio, A.
    Cubillo, A.
    Alonso-Gordoa, T.
    Carmona-Bayonas, A.
    Crespo, G.
    Blanco, M.
    Viudez, A.
    La Casta, A.
    Sevilla, I.
    Segura, A.
    Lopez, C.
    Benavent Vinuales, M.
    Nuciforo, P.
    Manzano, J. L.
    ANNALS OF ONCOLOGY, 2021, 32 : S914 - S915
12345